CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytomX Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.34+0.06 (+2.63%)
Close on Oct 19, 2026
- Market cap
- $512.32M
- P/E (TTM)
- –
- Dividend yield
- –
CytomX Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Market Cap | $509.88M | $164.85M |
| Enterprise Value | $179.60M | $87.06M |
| PS Ratio | 27.86 | 3.60 |
| PB Ratio | 1.69 | 2.03 |
| P/TBV Ratio | 1.69 | 2.31 |
Enterprise value
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 9.81 | 2.43 |
Income (trailing twelve months)
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Revenue | $18.30M | $57.94M |
| Operating Income | -$87.15M | -$21.44M |
| Pretax Income | -$79.42M | -$14.45M |
| Net Income | -$79.65M | -$22.46M |
| EBITDA | -$87.15M | -$16.91M |
| EPS (Diluted) | -$0.44 | -$0.83 |
Margins
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -476.2% | -44.5% |
| Pretax Margin | -434.0% | -13.0% |
| Profit Margin | -435.2% | -39.2% |
| EBITDA Margin | -476.2% | -31.3% |
| FCF Margin | -450.7% | -8.85% |
Returns
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -37.8% | -53.1% |
| Return on Assets (ROA) | -28.6% | -41.0% |
| Return on Capital Employed (ROCE) | -25.5% | -37.8% |
Growth
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -87.0% | 6.01% |
| Net Income Growth (YoY) | -266.0% | -37.7% |
| EPS Growth (YoY) | -178.6% | -29.2% |
| Revenue Growth (3Y CAGR) | 12.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.18% | 6.42% |
Balance sheet
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $330.28M | $62.42M |
| Net Cash (Debt) | $330.28M | $15.68M |
| Net Cash Per Share | $1.52 | $0.66 |
| Equity (Book Value) | $302.07M | $48.79M |
| Book Value Per Share | $1.39 | $1.36 |
| Tangible Book Value | $301.12M | $23.06M |
| Working Capital | $333.29M | $75.77M |
Financial position
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 9.36 | 3.30 |
| Quick Ratio | 9.23 | 2.39 |
Cash flow (trailing twelve months)
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$82.41M | -$12.35M |
| Capital Expenditures | -$74.00K | -$1.06M |
| Free Cash Flow | -$82.48M | -$20.28M |
| FCF Per Share | -$0.38 | -$0.42 |
Efficiency
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | 0.38 |
| Revenue Per Employee | $265.25K | $398.96K |
| Profits Per Employee | -$1.15M | -$703.34K |
| Employee Count | 69 | 74 |
Dividends and yields
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -15.6% | -22.7% |
| FCF Yield | -16.2% | -9.07% |
| Buyback Yield | -48.0% | -0.73% |
| Shareholder Yield | -48.0% | 0.00% |
Shares
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 217,899,000 | 58,179,650 |
| Shares Change (YoY) | 87.6% | 11.1% |
| Float | 214,615,000 | 49,173,100 |
| Shares Held by Insiders | 1.51% | 11.6% |
| Shares Held by Institutions | 97.9% | 59.4% |
Taxes
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Income Tax | $231.00K | $91.50K |
Scores
| Measure | CytomX Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 1.45 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from CytomX Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.